Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial

Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span

(2016) Ingrid Dieset et al.   SCHIZOPHRENIA BULLETIN

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis

(2016) Leonard Chiu et al.   SUPPORTIVE CARE IN CANCER

Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment

(2016) Mette Ø. Nielsen et al.   JAMA Psychiatry

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia

(2015) Fernando Caravaggio et al.   MEDICAL HYPOTHESES

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

(2014) Nicolai J. Wewer Albrechtsen et al.   DIABETOLOGIA

Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients

(2014) Bjørn H. Ebdrup et al.   JOURNAL OF CLINICAL PSYCHIATRY

Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior

(2014) Rozita H. Anderberg et al.   PHYSIOLOGY & BEHAVIOR

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

(2014) Pelle L Ishøy et al.   BMJ Open

Reference Values of Pulse Wave Velocity in Healthy People from an Urban and Rural Argentinean Population

(2014) Alejandro Díaz et al.   International Journal of Hypertension

Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder

(2013) L. Fredrik Jarskog et al.   AMERICAN JOURNAL OF PSYCHIATRY

Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes

(2013) Pelle L. Ishøy et al.   AMERICAN JOURNAL OF PSYCHIATRY

The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain

(2013) Meng He et al.   CNS DRUGS

Excess Mortality, Causes of Death and Life Expectancy in 270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and Sweden

(2013) Merete Nordentoft et al.   PLoS One

Oscillometric estimation of central blood pressure

(2012) Wolfgang Weiss et al.   BLOOD PRESSURE MONITORING

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

(2012) Bjørn H Ebdrup et al.   BMC Medicine

24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study

(2012) Leonella Luzardo et al.   HYPERTENSION RESEARCH

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

(2011) Katrina Weston-Green et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

(2010) Mark Fineman et al.   CLINICAL PHARMACOKINETICS

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’

(2010)   EUROPEAN HEART JOURNAL

Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

(2010) Lawrence Maayan et al.   NEUROPSYCHOPHARMACOLOGY

Obesity Among Those with Mental Disorders

(2009) David B. Allison et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Efficacy of behavioural interventions in managing atypical antipsychotic weight gain

(2009) J. M. Gabriele et al.   Obesity Reviews

Relation of obesity to consummatory and anticipatory food reward

(2009) Eric Stice et al.   PHYSIOLOGY & BEHAVIOR

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

(2009) R. W. Buchanan et al.   SCHIZOPHRENIA BULLETIN

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

(2008) J. McGrath et al.   EPIDEMIOLOGIC REVIEWS

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET